Profits jab higher at insulin maker Novo Nordisk
Novo Nordisk said Friday that its new treatment for adults who suffer from diabetes drove sales and profits higher, but the world's top manufacturer of insulin still faced difficulties in the key US market.
Nov 1, 2019
0
1